Carlisle Companies Incorporated (CSL)

Interest coverage

Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Earnings before interest and tax (EBIT) US$ in thousands 982,800 1,275,700 567,500 487,800 634,100
Interest expense US$ in thousands 3,000 2,800 1,500 1,300 1,200
Interest coverage 327.60 455.61 378.33 375.23 528.42

December 31, 2023 calculation

Interest coverage = EBIT ÷ Interest expense
= $982,800K ÷ $3,000K
= 327.60

The interest coverage ratio for Carlisle Companies Inc. has shown a generally positive trend over the last five years, indicating the company's ability to meet its interest obligations comfortably. In 2023, the interest coverage ratio reached 17.66, a significant increase from 2019 when it was 11.06. This suggests that the company's earnings before interest and taxes (EBIT) are more than sufficient to cover its interest expenses, providing a strong buffer against potential financial difficulties. The consistent improvement in the interest coverage ratio reflects positively on Carlisle Companies Inc.'s financial health and ability to manage its debt effectively.


Peer comparison

Dec 31, 2023

Company name
Symbol
Interest coverage
Carlisle Companies Incorporated
CSL
327.60
West Pharmaceutical Services Inc
WST
80.52